Track open bid opportunities, contracts, public meetings, and key contacts for The University of Texas MD Anderson Cancer Center.
Share your ICP and we will surface 10 ready-to-buy accounts using buying signals, competitor contracts, and procurement activity for free
See my top accountsActive opportunities open for bidding
Posted
Aug 28, 2026
Oct 13, 2026
The University of Texas System Supply Chain Alliance is seeking Preferred Suppliers to provide an Enterprise Research Administration Platform (eRA).
Key metrics and characteristics
City
The city where this buyer is located.
Houston
Enrollment
Total student enrollment.
359
IPEDS ID
Integrated Postsecondary Education Data System identifier.
416801
Employee FTE
Full-time equivalent employees.
50
Propensity to Spend
How likely this buyer is to spend on new technology based on operating budget trends.
AI Adoption Score
How likely this buyer is to adopt new AI technologies.
Startup Friendliness
How often this buyer champions startups and early adoption.
Latest Budget Year
Unlock to view
Operating Budget
Unlock to view
Includes fiscal year calendars, procurement complexity scores, and strategic insights.
Get alerted before the bid drops, know which RFPs to pursue, and generate compliant drafts with AI.
AI-ranked best-fit opportunities before bid boards
Auto-drafted, compliance-ready outlines & boilerplate
Competitor & pricing intel from past awards
Native sync to Salesforce & HubSpot
Track vendor wins and renewal opportunities
This contract formalizes the acquisition of a TissueScope LE120 RL Digital Slide Scanner and TissueSnap Preview Station from Huron Technologies International INC for MD Anderson's Genomic Medicine department, at a total purchase price of $269,000. It includes provisions for network connectivity to enable remote support and troubleshooting for the equipment, with an effective date of July 18, 2024, and a warranty period of one year.
This document details multiple work orders and change orders for Salesforce implementation and support services provided by Huron Consulting Services LLC to The University of Texas M. D. Anderson Cancer Center. The services cover Salesforce Provider Relationship Management (PRM), Salesforce Programmatic Initiatives, Salesforce Business Development CRM, and Salesforce Consumer Relationship Management (CRM), including Health Cloud and Marketing Cloud. These agreements are supplements and modifications to an overarching Information Technology Services Agreement (No. 5060013820) effective December 1, 2021. The earliest project effective date is January 6, 2023, with support for one project extending until December 2, 2024.
This is an Agreement for Software Provided as a Service between MD Anderson Cancer Center and Cayuse LLC. It covers the provision of proprietary research administration and grant management software modules (e.g., IACUC Protocol Management, eSirius Animal Inventory, Billing, Veterinary Care) as a SaaS solution, including a migration from an on-premise to a cloud-hosted environment. The initial contract term is 36 months, from September 1, 2020, to August 31, 2023, with options for two additional 12-month renewal periods. The total cost for this initial term is explicitly capped at $320,672.00, detailed in the fee schedule as yearly subscriptions.
This document is Amendment No. 63 to an existing agreement for Human Research Protection Program Software and Related Services between The University of Texas M. D. Anderson Cancer Center and Huron Consulting Services LLC. The original agreement was effective April 1, 2014. This amendment, effective October 1, 2025, incorporates Change Order No. 2 (CO#2), adding $30,000 for additional resource time to support a portal upgrade. The total proposed project budget, incorporating all prior and current change orders, is $120,000.
This document details a master agreement for Canvas LMS and Canvas Catalog services between The University of Texas M.D. Anderson Cancer Center and Instructure, Inc., originally effective April 1, 2024. The agreement has been amended multiple times to extend its term, increase the maximum spending limit (Cap Amount), and incorporate new service order forms and associated purchase orders. The latest services covered extend until March 31, 2027, and include various cloud subscriptions, custom URLs, and support services.
Board meetings and strategic plans from The University of Texas MD Anderson Cancer Center
The meeting addressed several agenda items, including the conflict of interest recusal for Dr. Shilpa S. Dhar regarding project RM00007811-RN00_AM5. Reports were presented by the Manager of Environmental Health & Safety and the Director of Environmental Health & Safety Administration, both stating nothing to report. The agenda included reviews of new protocols. For BSL-2 New Protocols, several protocols were approved with contingencies: RM00008602-RN00 concerning COVID Spike mRNA mix in animals, RM00004922-RN01 involving lung cancer promotion mechanisms via COPD condition, RM00004887-RN01 for a clinical protocol involving engineered NK cells in astrocytoma patients, RM00008586-RN00 involving melanoma cell lines and fecal microbiota transplantation, RM00008605-RN00 concerning CAR-T cell therapy for B-cell lymphoma, RM00001309-RN02 studying lung tissue regeneration, RM00008580-RN00 regarding an advanced melanoma study using a modified HSV1 virus, RM00001523-RN02 involving the functions of mutated mTOR, RM00008558-RN00 concerning efficacy in multiple myeloma, RM00007811-RN00_AM5 involving amendments to a protocol with lentiviral and non-viral vectors targeting gastric adenocarcinoma, RM00000781-RN02_AM8 adding an adenovirus backbone for a study on aging and Alzheimer's research, RM00006199-RN00_AM1 updating personnel and IACUC protocol numbers, RM00007111-RN00_AM7 with minor edits to an experimental plan, RM00002650-RN01_AM11 adding elements for transfer via MTA, RM00005849-RN00_AM60 updating an IACUC protocol number, RM00006297-RN00_AM8 updating an IACUC protocol number related to HIV-1 variants, RM00006717-RN00_AM9 adding retroviral backbones and HEK293 derived cell lines, RM00008452-RN00_AM1 adding a lentiviral plasmid, RM00000627-RN02_AM16 adding an objective related to aging and Alzheimer's research, RM00004137-RN01_AM2 adding agents for in vivo administration, RM00000599-RN02_AM10 involving extensive vector list consolidation, RM00006480-RN00_AM7 adding an adenovirus backbone and utilizing the sleeping beauty system, RM00000187-RN02_AM8 updating vector information, RM00004261-RN01_AM2 updating IACUC protocol and grant funding details, RM00000378-RN02_AM9 adding a new IACUC protocol, RM00000505-RN02_AM5 involving updates to various vectors and cell lines, RM00000201-RN02_AM2 updating an IACUC protocol number, and RM00003599-RN01_AM5 concerning the removal of human cell lines. Section 8 addressed Administrative Modifications for protocol RM00007111-RN00_AM8.
Public-sector contacts connected to The University of Texas MD Anderson Cancer Center.
Get relevant The University of Texas MD Anderson Cancer Center bid alerts
Track The University of Texas MD Anderson Cancer Center bids, renewals, public meetings, and contact changes matched to what you sell.
See expiring contracts, renewal timing, pricing history, and competitor awards, then sync the data to your CRM.
Expiring contracts, renewals, and award history
Competitor contract data and source files
Budget and spend signals to prioritize accounts
Native sync to Salesforce and HubSpot
The Institutional Biosafety Committee meeting addressed the approval of past meeting minutes, conflict of interest recusals related to specific projects involving Dr. Humam N. Kadara, and reports from the Adverse Events and Safety Committee. The primary focus was the review and approval of numerous new protocols falling under BSL-2, involving various investigators and protocols utilizing non-viral, viral, and microbial agents across different cell lines and animal systems. Several protocols were approved with contingencies pending clarifications or amendments, such as those involving gene manipulation for cancer research and vaccine candidate testing.
The meeting covered several topics, including a report of adverse events and safety committee updates. There was discussion and approval with contingencies for new BSL2 protocols involving viral and non-viral systems, cell lines, and microbial agents, focusing on studies related to cancer and immune responses. Modifications to existing protocols were also reviewed and approved, including updates to IACUC protocols and personnel changes.
Extracted from official board minutes, strategic plans, and video transcripts.
Track The University of Texas MD Anderson Cancer Center meetings, strategic plans, and budget discussions before the public bid appears.
Early signals from meeting minutes and plans
Vendor mentions and competitor tracking
Decision timeline from discussion to RFP
Quotable insights from buyer leadership
